Azanidazole: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Azanidazole.svg|Azanidazole | |||
</gallery> | |||
Latest revision as of 00:47, 20 February 2025
Azanidazole is a nitroimidazole antiprotozoal agent that is under investigation for the treatment of Chagas disease. It is being developed by the Drugs for Neglected Diseases initiative (DNDi) and has reached Phase II clinical trials.
Mechanism of action[edit]
Azanidazole works by inhibiting the synthesis of DNA in the parasite that causes Chagas disease, Trypanosoma cruzi. This prevents the parasite from multiplying and spreading in the body.
Clinical trials[edit]
In Phase II clinical trials, azanidazole was found to be effective in treating Chagas disease. However, further studies are needed to confirm these results and to determine the optimal dosage and duration of treatment.
Side effects[edit]
The most common side effects of azanidazole include nausea, vomiting, abdominal pain, and headache. In rare cases, it can cause neuropathy or leukopenia.
Development[edit]
The development of azanidazole is part of a larger effort to find new treatments for neglected diseases. The DNDi is a non-profit organization that works to develop new treatments for diseases that are neglected by the pharmaceutical industry, including Chagas disease.
